Related Experiment Video

Updated: Nov 6, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues

Martina Ferranti1, Giulia Tadiotto Cicogna1, Francesco Messina1

  • 1Department of Medicine-DIMED, Unit of Dermatology, University of Padova, Padova, Italy.

Immunotherapy
|May 6, 2021
PubMed
Abstract

No abstract available in PubMed .

Keywords:
anti-PD1 inhibitorsanti-PDL1 inhibitorsimmune-checkpoint inhibitorsimmune-related adverse eventsimmunotherapyrechallengeskin toxicities

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

783
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.0K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.1K